Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients

Melanoma Research

Volumn 10, Issue 1, 2000, Pages 55-65

  Bernengo, M G ^a   Quaglino, P ^a   Cappello, N ^a   Lisa, F ^a   Osella Abate, S ^a   Fierro, M T ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Biological response modifiers; Interleukin 12; Interleukin 2; Macrophage activation; Metastatic melanoma therapy; Multivariate analysis

Indexed keywords

CISPLATIN; INTERFERON; INTERLEUKIN 2; LACTATE DEHYDROGENASE; NEOPTERIN; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CELL SURVIVAL; DRUG EFFICACY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; IMMUNOTHERAPY; KILLER CELL; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SKIN METASTASIS; T LYMPHOCYTE SUBPOPULATION;

EID: 0034090909     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200010010-00008     Document Type: Article

References (60)

1. 1. Richards JM. Sequential chemoimmunotherapy for metastatic melanoma. Semin Oncol 1991; 18(suppl 7): 91-95.
2. 2. Khayat D, Borel C, Tourani JM, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alpha-2a for metastatic melanoma. J Clin Oncol 1993; 11: 2173-2180.
3. 3. Atzpodien J, Lopez-Hänninen E, Kirchner H, et al. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 1995; 31: 876-881.
4. 4. Bernengo MG, Doveil GC, Bertero M, et al. Low-dose integrated chemoimmunohormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma: a pilot study. Melanoma Res 1996; 6: 257-265.
5. 5. Antoine EC, Benhammouda A, Bernard A, et al. Salpetrière Hospital experience with biochemotherapy in metastatic melanoma. Cancer J Sci Am 1997; 3(suppl 1): S16-21.
6. 6. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16: 1752-1759.
7. 7. Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16: 2921-2929.
8. 8. Balch CM, Soong S, Murad TM, et al. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1: 126-134.
9. 9. Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998; 16: 1103-1111.
10. 10. Hoffmann R, Muller I, Neuber K, et al. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a. Br J Cancer 1998; 78: 1076-1080.
11. 11. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992; 10: 180-199.
12. 12. Ettinghausen SE, Moore JG, White DE, et al. Hematological effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 1987; 69: 1654-1660.
13. 13. Schneekloth C, Korfer A, Hadam M, et al. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo. Acta Haematol 1993; 89: 13-21.
14. 14. Von Rohr A, Ghosh AK, Thatcher N, et al. Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. Br J Cancer 1993; 67: 163-171.
15. 15. Farace F, Angevin E, Dietrich PY, et al. Low-dose IL-2 treatment: activation of discrete T-and NK-cell sub-populations in vivo. Int J Cancer 1995; 62: 523-528.
16. 16. Ellis TM, Creekmore SP, McMannis JD, et al. Appearance and phenotypic characterization of circulating Leu-19+ cells in cancer patients receiving recombinant interleukin-2. Cancer Res 1987; 47: 2020-2027.
17. 17. Atzpodien J, Kirchner H, Korfer A, et al. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha. Tumor Biol 1993; 3: 171-176.
18. 18. Kirkwood JM. Studies of interferons in the therapy of melanoma. Semin Oncol 1991; 18: 83-90.
19. 19. Lotze MT, Custer MC, Sharrow SO, et al. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res 1988; 47: 2188-2195.
20. 20. Lissoni P, Tisi E, Brivio F, et al. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2. Eur J Cancer 1991; 27: 1014-1016.
21. 21. Lopez-Hänninen EL, Korfer A, Hadam M, et al. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes. Cancer Res 1991; 51: 6312-6316.
22. 22. Soubrane C, Mouawad R, Ichen M, et al. Follow-up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. Clin Exp Immunol 1994; 95: 232-236.
23. 23. Vuoristo MS, Kellokumpu-Lehtinen P, Laine S, et al. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa. Immunopharmacol Immunotoxicol 1996; 18: 337-354.
24. 24. Blay JY, Negrier S, Combaret V, et al. Analysis of changes in serum levels of TNF, IL-1 and IL-6 during administration of IL-2. Correlation with clinical response to treatment. Bull Cancer 1992; 79: 55-65.
25. 25. Schaafsma MR, Falkenburg JHF, Landegent JE, et al. In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients. Blood 1991; 78: 1981-1987.
26. 26. Tilg H, Atkins MB, Dinarello CA, et al. Induction of circulating interleukin-10 by interleukin-1 and interleukin-2 but not interleukin-6 immunotherapy. Cytokine 1995; 7: 734-739.
27. 27. Buzaid AC, Grimm EA, Ali-Osman F, et al. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. Melanoma Res 1994; 4: 327-330.
28. 28. Lissoni P, Barni S, Ardizzoia A, et al. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients. J Biol Regulators Homeostatic Agents 1995; 9: 21-23.
29. 29. Anderson CM, Buzaid AC, Sussman J, et al. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Res 1998; 8: 149-155.
30. 30. Tartour E, Blay JY, Dorval T, et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 1996; 14: 1697-1703.
31. 31. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:475-480.
32. 32. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
33. 33. Orfanakis NG, Ostlund RE, Bishop CR, et al. Normal blood leukocyte concentration values. Am J Clin Pathol 1970; 53: 647-651.
34. 34. Hulstaert F, Hannet I, Deneys V, et al. Age-related changes in human blood lymphocyte subpopulations. Clin Immunol Immunopathol 1994; 70: 152-158.
35. 35. Faraggi D, Simon R. A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. Stat Med 1996; 15: 2203-2213.
36. 36. Cox DR. Regression models as life-tables. J R Stat Soc B 1972; 34: 187-220.
37. 37. Wolf SF, Sieburth D, Sypek J. Interleukin 12: a key modulator of immune function. Stem Cells 1994; 12: 154-168.
38. 38. Kishimoto T, Akira S, Narazaki M, et al. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243-1254.
39. 39. Moore KW, O'Garra A, de Waal Malefyt R, et al. Interleukin-10. Annu Rev Immunol 1993; 11: 165-190.
40. 40. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin: release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160: 310-316.
41. 41. Lissoni P, Fumagalli L, Di Felice G, et al. Prognostic significance of changes in IL-12 secretion during cancer immunotherapy with IL-2: preliminary considerations. Int J Immunother 1997; 13: 17-23.
42. 42. Palma JP, Aggarwal SK. Cisplatin and carboplatin-mediated activation of murine peritoneal macrophages in vitro: production of interleukin-1 alpha and tumor necrosis factor-alpha. Anticancer Drugs 1995; 6: 311-316.
43. 43. Keilholz U, Scheibenbogen C, Mohler T, et al. Addition of dacarbazine or cisplatin to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effects. Melanoma Res 1995; 5: 283-287.
44. 44. Bernengo MG, Lisa F, Meregalli M, et al. The prognostic value of T-lymphocyte levels in malignant melanoma. Cancer 1983; 52: 1841-1848.
45. 45. Scheibenbogen C, Goey S, Proebstle T, et al. Association of increased neopterin levels with response to therapy with CDDP and IFN-alpha/IL-2 but not with IFN-alpha/IL-2 alone in melanoma. Sixth International Congress on Anti-Cancer Treatment, Paris, France, 1996.
46. 46. Fierro MT, Lisa F, Novelli M, et al. Soluble interleukin-2 receptor, CD4 and CDS levels in melanoma: a longitudinal study. Dermatology 1992; 184: 182-189.
47. 47. Fierro MT, Bertero M, Novelli M, et al. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. Melanoma Res 1993; 3: 127-131.
48. 48. Gooding R, Riches P, Dadian G, et al. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br J Cancer 1995; 72: 452-455.
49. 49. Lissoni P, Pittalis S, Brivio F, et al. In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2. Cancer 1993; 71: 2076-2081.
50. 50. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998; 64: 275-290.
51. 51. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081-2095.
52. 52. Francis GM, Krohn EG, Woods KV, et al. Interleukin-6 production and secretion in human melanoma cell lines: regulation by interleukin-1. Melanoma Res 1996; 6:191-201.
53. 53 Sato T, McCue P, Masuoka K, et al. Interleukin 10 production by human melanoma. Clin Cancer Res 1996;2: 1383-1390.
54. 54. Mouawad R, Benhammouda A, Rixe O, et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 1996; 2: 1405-1409.
55. 55. Mouawad R, Khayat D, Merle S, et al. Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy? Melanoma Res 1999; 9: 181-188.
56. 56. Blay JY, Négrier S, Combaret V, et al. Serum levels of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317-3322.
57. 57. Paietta E, Nelson DL, Andersen J, et al. Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells. Med Oncol 1995; 12: 121-124.
58. 58. Yurockho AD, Nagarkatti PS, Nagarkatti M, et al. Tumor-induced alteration in macrophage accessory cell activity on autoreactive T cells. Cancer Immunol Immunother 1989; 30: 170-176.
59. 59. Fischer WH, Thor-Straten P, Terheyden P, et al. Function and dysfunction of CD4(+) T cells in the immune response to melanoma. Cancer Immunol Immunother 1999; 48: 363-370.
60. 60. Bajetta E, Del Vecchio M, Mortarini R, et al. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 1998; 4: 75-85.